Terms: = Leukemia AND SRC, c-SRC, 6714, ENSG00000197122, P12931, ASV, p60-Src, SRC1, c-src AND Treatment
458 results:
1. On the mechanism of wogonin against acute monocytic leukemia using network pharmacology and experimental validation.
Wang X; Wang Y; Chen J; Wang Q; Liu Z; Yin Y; Yang T; Shen T; Sa Y
Sci Rep; 2024 May; 14(1):10114. PubMed ID: 38698063
[TBL] [Abstract] [Full Text] [Related]
2. PHA-665752's Antigrowth and Proapoptotic Effects on HSC-3 Human Oral Cancer Cells.
Yadav AK; Wang S; Shin YM; Jang BC
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474118
[TBL] [Abstract] [Full Text] [Related]
3. ZAP-70 augments tonic B-cell receptor and CCR7 signaling in IGHV-unmutated chronic lymphocytic leukemia.
Chen J; Sathiaseelan V; Reddy Chilamakuri CS; Roamio Franklin VN; Jakwerth CA; D'Santos C; Ringshausen I
Blood Adv; 2024 Mar; 8(5):1167-1178. PubMed ID: 38113463
[TBL] [Abstract] [Full Text] [Related]
4. Osimertinib Covalently Binds to CD34 and Eliminates Myeloid leukemia Stem/Progenitor Cells.
Xia L; Liu JY; Yang MY; Zhang XH; Jiang Y; Yin QQ; Luo CH; Liu HC; Kang ZJ; Zhang CT; Gao BB; Zhou AW; Cai HY; Waller EK; Yan JS; Lu Y
Cancer Res; 2024 Feb; 84(3):479-492. PubMed ID: 38095536
[TBL] [Abstract] [Full Text] [Related]
5. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
[TBL] [Abstract] [Full Text] [Related]
6. Integrated bioinformatics analysis and network pharmacology to explore the potential mechanism of Patrinia heterophylla Bunge against acute promyelocytic leukemia.
Feng L; Zhu S; Ma J; Hong Y; Wan M; Qiu Q; Li H; Li J
Medicine (Baltimore); 2023 Oct; 102(40):e35151. PubMed ID: 37800842
[TBL] [Abstract] [Full Text] [Related]
7. Focal adhesion kinase activation by calcium-dependent calpain is involved in chronic lymphocytic leukaemia cell aggressiveness.
Severin F; Mouawad N; Ruggeri E; Visentin A; Martinello L; Pagnin E; Trimarco V; Pravato S; Angotzi F; Facco M; Trentin L; Frezzato F
Br J Haematol; 2023 Oct; 203(2):224-236. PubMed ID: 37495265
[TBL] [Abstract] [Full Text] [Related]
8. Ponatinib: An update on its drug targets, therapeutic potential and safety.
Gao Y; Ding Y; Tai XR; Zhang C; Wang D
Biochim Biophys Acta Rev Cancer; 2023 Sep; 1878(5):188949. PubMed ID: 37399979
[TBL] [Abstract] [Full Text] [Related]
9. Mechanism of Procyanidin B2 in the treatment of Chronic Myeloid leukemia Based on Integrating Network Pharmacology and Molecular Docking.
Li HX; Jing YX; Chai YH; Sun XH; He XX; Xue SL; Xi YM; Ma XL
Anticancer Agents Med Chem; 2023; 23(16):1838-1847. PubMed ID: 37246327
[TBL] [Abstract] [Full Text] [Related]
10. Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase.
Zhang C; Zhao X; Wang Z; Gong T; Zhao H; Zhang D; Niu Y; Li X; Zhao X; Li G; Dong X; Zhang L; Liu C; Xu J; Yu B
Invest New Drugs; 2023 Jun; 41(3):438-452. PubMed ID: 37097369
[TBL] [Abstract] [Full Text] [Related]
11. Novel 7-Chloro-4-aminoquinoline-benzimidazole Hybrids as Inhibitors of Cancer Cells Growth: Synthesis, Antiproliferative Activity, in Silico ADME Predictions, and Docking.
Krstulović L; Leventić M; Rastija V; Starčević K; Jirouš M; Janić I; Karnaš M; Lasić K; Bajić M; Glavaš-Obrovac L
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677600
[TBL] [Abstract] [Full Text] [Related]
12. A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors.
Karim NA; Ullah A; Wang H; Shoukier M; Pulliam S; Khaled A; Patel N; Morris JC
Curr Oncol; 2022 Dec; 29(12):9461-9473. PubMed ID: 36547158
[TBL] [Abstract] [Full Text] [Related]
13. Developing and Testing Methylated Nano-Structured Dipeptides that Inhibit src Kinase Activity In Vitro for Anti-Cancer Applications.
Nahhas AF; Nahhas AF; Webster TJ
J Vis Exp; 2022 Nov; (189):. PubMed ID: 36533825
[TBL] [Abstract] [Full Text] [Related]
14. Intracellular angiopoietin-1 promotes TKI-resistance via activation of JAK/STAT5 pathway in chronic myeloid leukemia.
Ma D; Liu P; Hu C; Zhou Z; Wang P; Wang Y; Zhang Y; Ran Y; Li P; Zhao J; Wang J; Zhang C; Tang L
Oncogene; 2023 Jan; 42(2):124-137. PubMed ID: 36385374
[TBL] [Abstract] [Full Text] [Related]
15. Rhodanine Derivatives as Anticancer Agents: QSAR and Molecular Docking Studies.
Molnar M; Lončarić M; Opačak-Bernardi T; Glavaš-Obrovac L; Rastija V
Anticancer Agents Med Chem; 2023; 23(7):839-846. PubMed ID: 36305127
[TBL] [Abstract] [Full Text] [Related]
16. SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma.
Huang CY; Chen LJ; Chen G; Chao TI; Wang CY
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232407
[TBL] [Abstract] [Full Text] [Related]
17. Novel pyrazolo[3,4-d]pyrimidines as dual src/Bcr-Abl kinase inhibitors: Synthesis and biological evaluation for chronic myeloid leukemia treatment.
Di Maria S; Picarazzi F; Mori M; Cianciusi A; Carbone A; Crespan E; Perini C; Sabetta S; Deplano S; Poggialini F; Molinari A; Aronne R; Maccioni E; Maga G; Angelucci A; Schenone S; Musumeci F; Dreassi E
Bioorg Chem; 2022 Nov; 128():106071. PubMed ID: 35932498
[TBL] [Abstract] [Full Text] [Related]
18. Evaluation of residue variability in a conformation-specific context and during evolutionary sequence reconstruction narrows drug resistance selection in Abl1 tyrosine kinase.
Otsuka FAM; Bjelic S
Protein Sci; 2022 Jul; 31(7):e4354. PubMed ID: 35762721
[TBL] [Abstract] [Full Text] [Related]
19. A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia.
Kasner MT; Halloran MB; Pan J; Ritchie EK; Fetterly GJ; Kramer D; Hangauer DG; Thompson JE
Invest New Drugs; 2022 Aug; 40(4):773-781. PubMed ID: 35579731
[TBL] [Abstract] [Full Text] [Related]
20. Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects.
Solman M; Blokzijl-Franke S; Piques F; Yan C; Yang Q; Strullu M; Kamel SM; Ak P; Bakkers J; Langenau DM; Cavé H; den Hertog J
Elife; 2022 May; 11():. PubMed ID: 35535491
[TBL] [Abstract] [Full Text] [Related]
[Next]
